{"id":"standard-of-care-for-gvhd","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion-related reactions"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rexlemestrocel-L works by promoting immune tolerance and reducing inflammation in the body. This is achieved through the administration of mesenchymal stem cells that have been engineered to express specific genes. The exact mechanisms by which these cells exert their effects are not fully understood, but they are thought to involve the modulation of various immune cell populations and the production of anti-inflammatory cytokines.","oneSentence":"Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:34.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease"}]},"trialDetails":[{"nctId":"NCT04990323","phase":"PHASE1, PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":"High Risk Myeloid Malignancies, Cord Blood Transplant","enrollment":13},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT04103879","phase":"PHASE2","title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2020-11-13","conditions":"High Risk Hematological Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT03441958","phase":"PHASE1, PHASE2","title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-03-07","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06874283","phase":"","title":"Ocular Complications From Cancer Therapy - Patient Registry and Biobank","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-05-13","conditions":"Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease","enrollment":150},{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT07025538","phase":"PHASE1","title":"Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-03-09","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":42},{"nctId":"NCT02340676","phase":"PHASE2","title":"A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-02","conditions":"Chronic Graft-versus-host-disease","enrollment":25},{"nctId":"NCT05922761","phase":"PHASE2","title":"BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-31","conditions":"Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases","enrollment":45},{"nctId":"NCT03954236","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-14","conditions":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","enrollment":24},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT04946721","phase":"","title":"2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2022-04-27","conditions":"Dry Eye Disease, oGVHD","enrollment":150},{"nctId":"NCT05333978","phase":"NA","title":"Optoacoustic Detection of Inflammation Using MSOT Device","status":"SUSPENDED","sponsor":"University of Oklahoma","startDate":"2022-05-31","conditions":"Graft Vs Host Disease, Colitis, Crohn Disease","enrollment":100},{"nctId":"NCT03121001","phase":"PHASE2","title":"Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-03-20","conditions":"Sickle Cell Disease","enrollment":50},{"nctId":"NCT06233110","phase":"PHASE1","title":"Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD","status":"RECRUITING","sponsor":"Stefanie Sarantopoulos, MD, PhD.","startDate":"2025-10-29","conditions":"Chronic Graft Versus Host Disease","enrollment":30},{"nctId":"NCT07349771","phase":"PHASE2","title":"Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-31","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":72},{"nctId":"NCT03121014","phase":"PHASE2","title":"Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2017-04-24","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":38},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT02782546","phase":"PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-30","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT06799195","phase":"PHASE2","title":"Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-06-23","conditions":"Hematological Malignancies, Graft-versus-Host Disease (GVHD)","enrollment":126},{"nctId":"NCT04581954","phase":"PHASE1, PHASE2","title":"Inflammatory Signal Inhibitors for COVID-19 (MATIS)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2020-10-02","conditions":"Coronavirus, Covid19, Pneumonia","enrollment":185},{"nctId":"NCT07162688","phase":"PHASE1, PHASE2","title":"Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.","status":"ENROLLING_BY_INVITATION","sponsor":"Fujian Medical University","startDate":"2025-05-16","conditions":"Graft-Versus-Host Disease(GVHD)","enrollment":30},{"nctId":"NCT02269150","phase":"PHASE2","title":"Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10","conditions":"Allogeneic Hematopoietic Stem Cell","enrollment":59},{"nctId":"NCT03913026","phase":"PHASE2","title":"UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2019-04-01","conditions":"High Risk Hematologic Malignancy, Cord Blood Transplant","enrollment":30},{"nctId":"NCT03068819","phase":"PHASE1, PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-23","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT07210242","phase":"","title":"HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR","status":"NOT_YET_RECRUITING","sponsor":"Ting YANG","startDate":"2025-10-10","conditions":"Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation","enrollment":300},{"nctId":"NCT03680092","phase":"PHASE2","title":"Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dimitrios Tzachanis, MD PhD","startDate":"2019-11-26","conditions":"GVHD, Hematologic Neoplasms","enrollment":43},{"nctId":"NCT04188912","phase":"","title":"Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-09-13","conditions":"Hematopoietic and Lymphoid Cell Neoplasm","enrollment":267},{"nctId":"NCT06569082","phase":"NA","title":"CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-10-31","conditions":"Graft Failure, Poor Graft Function","enrollment":21},{"nctId":"NCT05823571","phase":"PHASE1","title":"Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-07-06","conditions":"Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic","enrollment":32},{"nctId":"NCT07157514","phase":"PHASE2, PHASE3","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2026-01","conditions":"Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia","enrollment":306},{"nctId":"NCT04822766","phase":"NA","title":"A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-31","conditions":"Acute Myeloid Leukemia","enrollment":24},{"nctId":"NCT03456817","phase":"PHASE2","title":"HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2020-07-01","conditions":"Graft-versus-host-disease, Relapse","enrollment":68},{"nctId":"NCT05673876","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2023-04-06","conditions":"Acute Graft-versus-host Disease","enrollment":7},{"nctId":"NCT04852692","phase":"","title":"A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2021-06-21","conditions":"Chronic Graft vs Host Disease","enrollment":15},{"nctId":"NCT01350245","phase":"PHASE2","title":"Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2010-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia","enrollment":28},{"nctId":"NCT05090384","phase":"PHASE2","title":"Pediatric GVHD Low Risk Steroid Taper Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"John Levine","startDate":"2022-10-20","conditions":"Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":50},{"nctId":"NCT03755414","phase":"PHASE1","title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-09-04","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes","enrollment":55},{"nctId":"NCT04291261","phase":"PHASE2","title":"Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2020-05-18","conditions":"Acute-graft-versus-host Disease","enrollment":24},{"nctId":"NCT06839456","phase":"PHASE1, PHASE2","title":"Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-03-21","conditions":"Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT04314219","phase":"PHASE3","title":"Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients","status":"RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2021-08-15","conditions":"Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission","enrollment":264},{"nctId":"NCT03967379","phase":"NA","title":"Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-02-01","conditions":"Other Cancer","enrollment":60},{"nctId":"NCT02218151","phase":"NA","title":"Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2","status":"TERMINATED","sponsor":"Duke University","startDate":"2014-09-03","conditions":"Blood Disorders","enrollment":61},{"nctId":"NCT03524235","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL","status":"COMPLETED","sponsor":"Noah Merin","startDate":"2018-07-18","conditions":"Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia","enrollment":20},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02061800","phase":"PHASE1, PHASE2","title":"CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diane George","startDate":"2013-06-03","conditions":"Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)","enrollment":14},{"nctId":"NCT04014790","phase":"PHASE2","title":"RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Regimmune Corporation","startDate":"2019-11-25","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Acute-graft-versus-host Disease","enrollment":49},{"nctId":"NCT04539470","phase":"PHASE1","title":"Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-11-19","conditions":"Acute Graft-versus-host Disease","enrollment":18},{"nctId":"NCT06279585","phase":"NA","title":"Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD","status":"UNKNOWN","sponsor":"University of Seville","startDate":"2024-03-01","conditions":"Graft-versus-host-disease, Graft Versus Host Disease, Chronic, Stem Cell Transplant Complications","enrollment":108},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":"Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma","enrollment":""},{"nctId":"NCT02525029","phase":"PHASE1, PHASE2","title":"Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-03","conditions":"Graft vs Host Disease","enrollment":53},{"nctId":"NCT02917096","phase":"PHASE1","title":"Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2016-11-13","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":18},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia","enrollment":6},{"nctId":"NCT03699475","phase":"PHASE2, PHASE3","title":"Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS","status":"TERMINATED","sponsor":"Bellicum Pharmaceuticals","startDate":"2018-12-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT02641236","phase":"PHASE2","title":"Gut Decontamination In Pediatric Allogeneic Hematopoietic","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-03","conditions":"Hematopoietic Stem Cell Transplantation (HSCT), Acute GVH Disease","enrollment":24},{"nctId":"NCT05508009","phase":"PHASE1, PHASE2","title":"Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor","status":"RECRUITING","sponsor":"Alice Bertaina","startDate":"2023-01-10","conditions":"SIOD, Cystinosis, FSGS","enrollment":12},{"nctId":"NCT03067155","phase":"PHASE2","title":"CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-10","conditions":"Hematological Malignancies, CMV Infection","enrollment":1},{"nctId":"NCT04059757","phase":"PHASE2","title":"Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD","status":"WITHDRAWN","sponsor":"Leland Metheny","startDate":"2022-05","conditions":"Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)","enrollment":""},{"nctId":"NCT04594031","phase":"PHASE1","title":"US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease","status":"WITHDRAWN","sponsor":"ExCellThera inc.","startDate":"2021-07-13","conditions":"Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation","enrollment":""},{"nctId":"NCT00366145","phase":"PHASE3","title":"Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2006-08-17","conditions":"Graft Versus Host Disease","enrollment":260},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT00001880","phase":"PHASE2","title":"Stem Cell Transplantation for Metastatic Solid Tumors","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-03-12","conditions":"Neoplasm Metastasis","enrollment":42},{"nctId":"NCT02806947","phase":"PHASE2","title":"A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2016-10","conditions":"Acute GVHD","enrollment":127},{"nctId":"NCT03339297","phase":"PHASE2","title":"An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2018-02-21","conditions":"Graft-versus-host Disease, Acute-graft-versus-host Disease","enrollment":152},{"nctId":"NCT02406651","phase":"PHASE1, PHASE2","title":"Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD","status":"COMPLETED","sponsor":"EVIVE Biotechnology","startDate":"2016-05-12","conditions":"Acute Graft vs Host Disease","enrollment":30},{"nctId":"NCT02588339","phase":"PHASE2","title":"Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Graft Versus Host Disease, GVHD","enrollment":42},{"nctId":"NCT01690520","phase":"PHASE2","title":"Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Nohla Therapeutics, Inc.","startDate":"2012-12-11","conditions":"Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission","enrollment":163},{"nctId":"NCT03066466","phase":"PHASE3","title":"Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT","status":"WITHDRAWN","sponsor":"Loyola University","startDate":"2019-12-10","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT03862079","phase":"PHASE2","title":"Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-01","conditions":"Graft-versus-host Disease Prevention","enrollment":""},{"nctId":"NCT01380535","phase":"EARLY_PHASE1","title":"Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2011-11","conditions":"Chronic Graft Versus Host Disease","enrollment":60},{"nctId":"NCT01379209","phase":"PHASE1, PHASE2","title":"Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)","status":"COMPLETED","sponsor":"Regimmune Corporation","startDate":"2011-09","conditions":"Graft Versus Host Disease","enrollment":68},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT02728895","phase":"PHASE1","title":"Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-06-15","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":24},{"nctId":"NCT01875237","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-12-27","conditions":"Leukemia, Myeloma, Myeloproliferative Diseases","enrollment":3},{"nctId":"NCT00709592","phase":"PHASE2","title":"Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2008-07-21","conditions":"Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma","enrollment":42},{"nctId":"NCT03118661","phase":"PHASE1","title":"Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2018-03-19","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT01790568","phase":"PHASE2","title":"Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-12","conditions":"Graft vs Host Disease, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder","enrollment":26},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT01491958","phase":"PHASE2","title":"Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-12-10","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome","enrollment":40},{"nctId":"NCT02765997","phase":"PHASE2","title":"StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":""},{"nctId":"NCT00054613","phase":"PHASE2","title":"Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2002-06","conditions":"Graft-versus-Host Disease","enrollment":72},{"nctId":"NCT01754389","phase":"PHASE2","title":"Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01","conditions":"Graft Versus Host Disease","enrollment":138},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT01471067","phase":"PHASE1","title":"Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-07-13","conditions":"Blood And Marrow Transplantation, Leukemia, Lymphoma","enrollment":33},{"nctId":"NCT00775632","phase":"PHASE2","title":"Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2008-10","conditions":"Graft Versus Host Disease, Bone Marrow Transplantation","enrollment":78},{"nctId":"NCT01754454","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2012-12","conditions":"Acute GVH Disease","enrollment":30},{"nctId":"NCT01589549","phase":"PHASE2","title":"Mesenchymal Stromal Cells for Acute Graft Versus Host Disease","status":"UNKNOWN","sponsor":"R.P.Herrmann","startDate":"2012-04","conditions":"Acute GVH Disease","enrollment":66},{"nctId":"NCT00031824","phase":"PHASE3","title":"Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-04","conditions":"Graft Versus Host Disease","enrollment":82},{"nctId":"NCT00675441","phase":"PHASE2","title":"Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-04","conditions":"Graft-versus-Host Disease","enrollment":5},{"nctId":"NCT01964625","phase":"NA","title":"Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2010-11","conditions":"Chronic Graft Versus Host Disease","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","companyName":"Mesoblast, Inc.","companyId":"mesoblast-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease. Used for Graft-versus-host disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}